Latest Share Chat

ValiRx Share News (VAL)

ValiRx Information

Buy VAL Shares
Add VAL to Watchlist
Add VAL to Alert

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1.90

Bid: 1.80

Ask: 2.00

Change: 0.30 (15.79%)

Spread: 0.20 (11.111%)

Open: 1.90

High: 2.20

Low: 2.20

Prev. Close: 1.90

Last checked at -

ValiRx Says VAL201 Dose Escalation Complete, Preparing VAL401 Trials

Thu, 19th Nov 2015 11:40

LONDON (Alliance News) - Life sciences company ValiRx PLC on Thursday said the dose escalation portion of the phase 1/2 clinical trial for its VAL201 cancer compound is set to be completed.

The compound showed safety and tolerability in the trials and no significant adverse effects have been recorded, ValiRx said.

The company also said it has drafted the protocols and associated files to be submitted to start trials on its VAL401 compound.

Shares in ValiRx were down 4.1% to 23.01 pence on Thursday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

More News

20 Dec 2021 15:00

TRADING UPDATES: InnovaDerma sees profit return; ValiRx amends licence

20 Dec 2021 12:17

ValiRx amends longstanding licence deal with Cancer Research Technology

(Sharecast News) - Cancer therapeutics developer ValiRx announced on Monday that it has amended and restated the licence for the VAL201 peptide held by the company from Cancer Research Technology (CRT) to enable a range of sub-licensing options.

2 Nov 2021 14:34

TRADING UPDATES: Custodian sells car showroom; Samarkand buys Napiers

2 Nov 2021 09:57

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

16 Sep 2021 18:19

IN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment

7 Sep 2021 15:05

EARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips

6 Jul 2021 13:00

ValiRx adds three new patents in first half

(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.

27 May 2021 20:17

TRADING UPDATES: Brave Bison, Strix Group see strong performances

27 May 2021 13:54

ValiRx terminates peptide drug candidate deal

(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.

20 May 2021 16:07

UK shareholder meetings calendar - next 7 days

28 Apr 2021 15:30

EXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo

27 Apr 2021 11:32

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

15 Feb 2021 16:04

Physiomics and ValiRx enter new collaboration deal

(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.

15 Feb 2021 11:05

IN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics

19 Jan 2021 16:53

Latest Share Chat

ValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx Says VAL201 Dose Escalation Complete, Preparing VAL401 Trials

Login to your account

Quickpicks are a member only feature

Login to your account